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Uterine artery embolisation (UAE) is a relative newcomer to the mainstream treatment modalities available for ﬁbroid-related
problems. The eﬃcacy of UAE is indisputable and has been shown to be comparable to hysterectomy in the short term in large-
scale trials. Moreover, compared with hysterectomy, UAE is less invasive, carries a superior risk proﬁle, and, importantly, preserves
the uterus. UAE therefore oﬀerspatientssymptomreliefwhilstatthesametimeretainingreproductivepotential.Notably however,
although women can have successful pregnancies following UAE, it is becoming increasingly evident that pregnancies after UAE
aremoreriskyespeciallyduringtheearlystages.Long-termoutcomedatafromrandomisedtrialsinvolvingUAEhaveveryrecently
become available and show that whilst high satisfaction rates previously identiﬁed during early-stage followup are sustained, one
notable drawback is a substantial risk of reintervention. It remains to be seen how this facet of UAE will impact on its future
uptake.
1.Introduction
The occlusion of the vascular supply of uterine ﬁbroids,
uterine artery embolisation (UAE), was ﬁrst described in
1995[1]andisnowﬁrmlyestablishedasaminimallyinvasive
organ-preserving approach for treating symptomatic uterine
ﬁbroids. Short term followup data from randomised con-
trolled trials have established UAE as a safe and eﬀective
alternative to hysterectomy for alleviating ﬁbroid-related
disorders such as menorrhagia and pressure symptoms [2].
However, a fuller appreciation of the longer term eﬃcacy
and complications of UAE is only just becoming apparent.
Therefore, although gaining in popularity, it is important
that patients be apprised of these emerging data so that they
will be well equipped to make informed decisions regarding
the suitability of this treatment modality. This paper will
summarise the reported side eﬀects, complications, and
symptom recurrence rate, not only in the short term but, as
5-year followup data are starting to emerge, also in the long
term.Wewillalsoreviewtheavailableevidenceregardingthe
adverse eﬀects of UAE on fertility and pregnancy outcome.
2. Technical Aspects andPeriprocedural
Side Effects of UAE
UAEexploitsthediﬀerentialrecoveryabilitybetweenﬁbroids
and normal uterine tissue in response to ischaemia that is
induced at the arteriolar level [3]. Using a femoral artery
approach, the uterine artery is catheterised thereby allowing
for the injection of embolic particles, most often made of
poly-vinyl alcohol (PVA), that disrupt the blood supply
to the ﬁbroid (hence the alternative term Uterine Fibroid
Embolisation or UFE). As ﬁbroids derive their blood supply2 Obstetrics and Gynecology International
from both sides in nearly all cases, the procedure is repeated
bilaterally altogether taking up to around 90 minutes to
complete [4].
Pelvic pain is the most commonly reported side eﬀect
of UAE. The most likely causes are ischaemia of the ﬁbroid
and temporary ischaemia of the myometrium. The onset of
the pain can be immediate, and it usually lasts about 12
hours. Hence, an overnight stay with adequate pain relief
is usually required after the procedure. More severe pain
usually subsides within the ﬁrst 24 hours but moderate pain
may persist for up to 2-3 days. Nausea typically accompanies
the pain and usually requires pharmacological management
[4].
Bruno and colleagues reported on the recovery of 99
patients who underwent UAE [5]. All patients in their
study had an overnight stay and received a combination
of intravenous NSAID (ketorolac) and patient-controlled
administration of intravenous morphine. Based on a visual
analogue scale of 0–10 (where 0 is no pain and 10 worst
imaginablepain),themeanpainscoresovertheﬁrst24hours
and ﬁrst week were 3.03 and 4.83, respectively. Recovery was
fairly fast, with the vast majority (94%) of patients missing
less than 10 days of work [5].
Another frequent morbidity of UAE is postembolisation
syndrome, which includes fever, pain, malaise, and nausea
and lasts from a few hours to a few days. The syndrome
typically occurs after embolisation of any solid organ and
is thought to be an immune-mediated response. It has been
reported to occur in ∼50% of patients but is easily controlled
with analgesics, antipyretics, and anti-inﬂammatories [6].
3.AdverseEventsAssociatedwithUAE
Large multicentre trials have consistently reported low rates
of adverse events associated with UAE. Adverse eﬀects can be
categorised into major, minor, and severe, with the majority
of them presenting within the ﬁrst month after procedure
[6].
The largest series to have assessed adverse eﬀects, the
FIBROID registry, enrolled 3000 patients [7]a n dr e p o r t e d
a 0.66% rate of in-hospital major adverse events and a 4.8%
rate within the ﬁrst 30 days following discharge. Table 1
summarises the important complications in the acute (≤24
hours after UAE), subacute (>24 hours to up to 1 week
after UAE) and chronic (>1 week postoperatively) phases.
Although pain is often a nonspeciﬁc side eﬀect, it is
imperative for the treating clinician to be aware that pain
that is more intractable could be a harbinger of a more
sinister underlying complication such as endometritis, pelvic
abscess formation, or endometrial ischaemic necrosis that
wouldrequireclinicalandlaboratoryevaluationandpossibly
further imaging [6].
A frequent complication of UAE reported in up to 3%
of cases is the vaginal expulsion of an infarcted ﬁbroid
often requiring further intervention [8]. This complication
is thought to arise when UAE is used in the presence of
either submucosal ﬁbroids or intramural ﬁbroids that have
a substantial submucosal component. Imaging in the form
Table 1




Transient or permanent amenorrhoea
Sepsis Endometritis
Bleeding Urinary retention
Groin haematoma Passage of ﬁbroid tissue
Contrast reaction Delayed contrast reaction
Vasovagal response Tuboovarian abscess
Pulmonary embolus Uterine necrosis and rupture
of a contrast-enhanced MRI is helpful in evaluating the
size of the infarcted fragment and its degree of extrusion
into the uterine cavity as well as the extent of tissue that
remains adherent to the surrounding myometrium. In cases
in which a partially infarcted ﬁbroid remains ﬁrmly attached
tothemyometrium,hysteroscopicresectionordilatationand
curettage may be required.
Uterine infection is a more serious complication and
patients may present with severe pain of sudden onset,
vaginal discharge, and/or bleeding. Infection needs to be
aggressively treated as it may lead to systemic sepsis and,
occasionally, could require hysterectomy [9]. Very rarely,
death due to overwhelming sepsis has also been described
[10]. Fortunately, it is a relatively rare complication having
been reported in less than 1% of cases [9].
Another rare but also potentially fatal complication
of UAE is pulmonary embolism, which is thought to be
attributed to a transient hypercoagulable state similar to,
but not as severe as, that seen with surgical procedures
[4, 11]. The incidence has been estimated to be 1 in 400 [12]
making it prudent to undertake a thromboprophylaxis risk
assessment prior to UAE.
Oﬀ-target organ embolisation has also been documented
and is most likely to aﬀect the ovaries (discussed in more
detail later). Although the vaginal artery usually arises as a
separate branch of the internal iliac artery, it may at times
share a common trunk with the uterine artery or form
anastomoses within the broad ligament. Under such cir-
cumstances, the vagina becomes vulnerable to embolisation-
induced ischaemia [6] resulting in sexual dysfunction and/or
dyspareunia [13].
Despite all of the above, the evidence from multicentre
trials consistently shows that the rate of major adverse
events following UAE is signiﬁcantly lower than those
related to more conventional surgical interventions such
as myomectomy and hysterectomy. In the REST trial, a
UK-based multicentre trial that recruited 157 women with
symptomatic ﬁbroids, the major complication rate for UAE
in the ﬁrst year, was 12% compared to 20% for surgical
patients [14]. Similarly, in the HOPEFUL trial, a UK trial
involving 18NHS trusts, the complication rate was 4.5% for
UAE compared with 14.8% for surgically managed patients
[15]. In the EMMY trial, a randomised controlled trial
conducted in The Netherlands involving 177 patients, whenObstetrics and Gynecology International 3
bloodtransfusionwasincludedinthecalculations,themajor
complication rate in the surgically treated group was 14.5%
whilethemajorcomplicationrateassignedtotheUAEgroup
was only 1.3% [16].
4. Fertilityafter UAE
There is accumulating evidence that women can and do
conceive after UAE. However, it is becoming increasingly
apparent that UAE is associated with a greater risk of
pregnancy complications. On the basis of this, a desire to
maintain fertility is listed as a relative contraindication for
UAE in the joint Standards of Practice recently set out by
the Cardiovascular and Interventional Radiological Society
of Europe and the Society of Interventional Radiology [17].
The only randomised controlled trial to have addressed
fertilityafterUAEcomparedpregnanciesfollowingmyomec-
tomy (laparoscopic and open) with those following UAE
in women who were desirous of future pregnancies [18].
Results from this trial favoured myomectomy in the short
term (up to 2 years after treatment) suggesting a beneﬁt of
laparoscopic myomectomy over UAE in terms of likelihood
of conceiving (77.5% versus 50%) and a relative risk of not
getting pregnant following UAE of 2.22 [18].
Fertility would also be severely jeopardised if oﬀ-target
eﬀects of UAE were to compromise ovarian function.
As discussed previously, oﬀ-target eﬀects on the ovarian
vasculature arising from uteroovarian collaterals are well
documented. This results in ovarian ischaemia, depletion of
ovarian follicles, and a risk of premature menopause. This
catastrophic eﬀect is mostly seen amongst patients over 45
years of age [19] perhaps because their pretreatment ovarian
reserve is likely to have been low. Notably however, younger
women are not immune to this complication [20]. In a
study measuring FSH levels before and after procedure, 6%
of women experienced transient postmenopausal symptoms
including amenorrhoea, hot ﬂushes, and elevated FSH levels,
most of which resolved by 10 months after UAE [21].
5. Risk of Miscarriage after UAE
Although mainly observational in nature, one of the most
striking aspects regarding the impact of UAE on pregnancy
outcome pertains to miscarriage rates. Amongst women
conceiving following UAE, spontaneous miscarriage rates
range from 18.2% [22] to as high as 64.3% [23]( Table 2).
Strikingly, based on currently available data, the cumulative
risk of miscarriage after UAE is ∼35% (Table 2), threefold
higher than rates in the general population [24, 25].
Two parameters known to independently inﬂuence mis-
carriage rates are maternal age and ﬁbroid location. Thus,
older women are exquisitely susceptible to miscarriage due
to their increased risk of having pregnancies with abnormal
chromosomal compliments [26, 27]w h e r e a sﬁ b r o i ds u b -
types which distort the uterine cavity (submucosal ﬁbroids)
have the most deleterious eﬀect on miscarriage. A recent
review that used pooled data from previously published
series compared the risk of miscarriage after UAE with that
Table 2
Study N Miscarriage (%)
Goldberg and Pereira, 2006 [31] 51 12 (23.5)
Pron et al., 2005 [22] 22 4 (18.2)
Walker and McDowell, 2006 [32] 53 17 (32.1)
Holub et al., 2007 [23] 24 14 (58.3)
Mara et al., 2008 [18] 14 9 (64.3)
Hirst et al., 2008 [33] 34 15 (44.1)
Cumulative data 198 71/198 (35.9)
in women who had untreated ﬁbroids and matched groups
f o ra g ea n dﬁ b r o i dl o c a t i o n[ 24]. Even after controlling for
these two parameters, the risk of miscarriage after UAE was
∼35% compared to ∼16% in ﬁbroid-containing pregnancies
(odds ratio 2.8, 95% conﬁdence interval 2.0–3.8) [24]. These
data regarding UAE are counterintuitive to the notion that
treatment of ﬁbroids should reduce miscarriage rates and
point to a detrimental impact of the UAE procedure on the
uterine milieu.
It is unclear why UAE imposes additional risks for
miscarriage over and above those known to be associated
with ﬁbroids [24]. One possibility is that endometrial
ischaemia following UAE permanently alters the quality
of potential implantation sites, making it hostile to the
early conceptus. Fibroid migration and distortion of the
endometrial contour has also been implicated as a causative
factor for miscarriage. In line with this, amongst 51 women
who underwent UAE for intramural ﬁbroids and were
followed up by hysteroscopy, intrauterine protrusion of the
ﬁbroid remnant was documented in 37% of cases, whilst
adhesions were reported in 14% and in 10% of instances
there was a communication between the myoma and the
endometrial cavity [28]. Indeed, only 37% of women had
a hysteroscopically normal cavity [28]. The above factors,
along with other currently unknown downstream eﬀects
of UAE, likely contribute to the increased risk of early
pregnancy failure.
6. Obstetric Outcomes after UAE
Although the foregoing data clearly identify early pregnancy
asavulnerablestagefollowingUAE,laterstagesofpregnancy
are not immune. The parameters used to evaluate the impact
of UAE on obstetric performance have included preterm
birth rates, mode of delivery, fetal presentation, fetal growth
restriction, and postpartum haemorrhage. Recent studies
have amalgamated these parameters from observational and
cohort studies, together comprising over 200 pregnancies
after UAE [24, 25]( Table 3). Compared with women having
ﬁbroid uteri who had received no intervention, it is evident
that the rates of Caesarean section delivery and postpartum
haemorrhage (PPH) are signiﬁcantly increased after UAE
[24, 25].
As acknowledged previously, important caveats need to
be borne in mind when interpreting these comparative
data involving UAE. Notably, the control group includes4 Obstetrics and Gynecology International
Table 3
Obstetric complication General population (%) After UAE (%)
Postpartum haemorrhage 6 13.8
Preterm delivery 10 17.3
Caesarean delivery 22 67.5
IUGR 10 8
Malpresentation 5 9.4
women who, although possessing ﬁbroids, were asymp-
tomatic making it likely that they, on average, had smaller
and fewer ﬁbroids. In addition, other confounding factors
that could potentially impact on pregnancy outcome such
as body mass index (BMI) and parity were inconsistently
reported and could not therefore be controlled for. Also, the
increased risk of Caesarean delivery following UAE could
reﬂect patient preference or the clinician’s reluctance in
advising a trial of labour in women considered to be at
high risk rather than a robust indication for abdominal
delivery due to eﬀects directly ascribable to UAE per se.
Similarly, the increased risk of PPH may be a consequence
of the increased rates of Caesarean delivery rather than any
predisposition to uterine haemorrhage brought about by
embolisation. Reassuringly, there was no increase in risks of
preterm delivery, malpresentation, or fetal growth restriction
in the pregnancies that successfully negotiated the early
stages of gestation [24, 25].
7. Risk of Recurrence after UAE
A very important aspect of UAE that has recently become
apparent with the publication of longer-term followup data
is a substantial risk of requiring reintervention. Although
not a complication per se, this is a signiﬁcant revelation
that patients need to be cognisant of as it could sway their
decision-making towards more radical treatment modalities
such as hysterectomy if the desire to avoid reintervention is a
high priority.
Long-term data from observational studies conﬁrm that
although UAE is eﬀective, there is a recurrence rate of
about 20% at 5 years [4], deﬁned as subsequent need
for hysterectomy, myomectomy, or repeat embolisation.
Recently, the 5-year results from the EMMY and REST
randomised controlled trials were published and point to an
evenhigher rateof reintervention. In the EMMYtrial ofUAE
(88 patients) versus hysterectomy (89 patients) for symp-
tomatic uterine ﬁbroids, 23 of 81 (28.4%) of UAE patients
subsequently underwent a hysterectomy due to insuﬃcient
improvement of symptoms [29]. More recently, long-term
followup results were reported for the REST trial, during
which women were randomised to either UAE (106 patients)
or surgery (42 hysterectomies and 9 myomectomies), and
show a very similar 5-year intervention rate of 32% in the
UAE group versus only 4% in the surgery group [30]. One
very notable consequence of this degree of reintervention
was that the initial cost beneﬁt of UAE over surgery that was
observed at 12 months was substantially reduced at 5 years,
making both treatments cost neutral [30].
8. Conclusion
UAE for ﬁbroids is a safe and eﬀective minimally invasive
treatment that promises substantial improvement in symp-
tom control for women seeking a uterine-sparing therapy.
However, it remains to be seen whether the longer-term
need for reintervention in almost one-third of cases inﬂu-
ences patient uptake of the procedure. Moreover, with an
increasingly ﬁnancially conscious health service, the longer-
term dissipation of the short-term cost beneﬁts of UAE over
surgery could inﬂuence how widely this therapeutic option
is oﬀered. For women desirous of preserving future fertility,
careful counselling of the potential risks associated with
ensuing pregnancies is paramount. The available evidence,
albeit very limited, suggests that myomectomy may be the
treatment of choice in such women providing surgery is a
viable option. Further prospective research on the impact
of UAE on reproductive performance is needed before more
deﬁnitive conclusions can be drawn.
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